The DOI matches its Crossref record; 249 of the 249 references it cites were found in a registry or an index.
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Abstract
During the past decade, proof of the principle that peptide receptors can be used successfully for in vivo targeting of human cancers has been provided. The molecular basis for targeting rests on the in vitro observation that peptide receptors can be expressed in large quantities in certain tumors. The clinical impact is at the diagnostic level: in vivo receptor scintigraphy uses radiolabeled peptides for the localization of tumors and their metastases. It is also at the therapeutic level: peptide receptor radiotherapy of tumors emerges as a serious treatment option. Peptides linked to cytotoxic agents are also considered for therapeutic applications. The use of nonradiolabeled, noncytotoxic peptide analogs for long-term antiproliferative treatment of tumors appears promising for only a few tumor types, whereas the symptomatic treatment of neuroendocrine tumors by somatostatin analogs is clearly successful. The present review summarizes and critically evaluates the in vitro data on peptide and peptide receptor expression in human cancers. These data are considered to be the molecular basis for peptide receptor targeting of tumors. The paradigmatic peptide somatostatin and its receptors are extensively reviewed in the light of in vivo targeting of neuroendocrine tumors. The role of the more recently described targeting peptides vasoactive intestinal peptide, gastrin-releasing peptide, and cholecystokinin/gastrin is discussed. Other emerging and promising peptides and their respective receptors, including neurotensin, substance P, and neuropeptide Y, are introduced. This information relates to established and potential clinical applications in oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–249 of 249
Bussolati, G., Cassoni, P., Ghisolfi, G., Negro, F., & Sapino, A. (1996) · Europe PMC (PubMed Central) · Cited by 65
Gastrin-Releasing Peptide Is a Growth Factor for Human Neuroblastomas
Kim, S., Hu, W., Kelly, D. R., Hellmich, M. R., Evers, B. M., & Chung, D. H. (2002) · Annals of Surgery · doi:10.1097/00000658-200205000-00003 · Cited by 65
Poinot‐Chazel, C., Portier, M., Bouaboula, M., Vita, N., Pecceu, F., Gully, D., Monroe, J. G., Maffrand, J., Fur, G. L., & Casellas, P. (1996) · Biochemical Journal · doi:10.1042/bj3200145 · Cited by 65
Kimura, N., Hayafuji, C., Konagaya, H., & Takahashi, K. (1986) · Endocrinology · doi:10.1210/endo-119-3-1028 · Cited by 64
Moody, T. W., Chiles, J., Casibang, M., Moody, E., Chan, D. C. F., & Davis, T. P. (2001) · Peptides · doi:10.1016/s0196-9781(00)00362-4 · Cited by 64
Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease.
Wang, L., Frieß, H., Zhu, Z., Graber, H. U., Zimmermann, A., Korc, M., Reubi, J. C., & Büchler, M. W. (2000) · PubMed · Cited by 64
Self-citationHalmos, G., Schally, A. V., Sun, B., Davis, R., Bostwick, D. G., & Płonowski, A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6698 · Cited by 63
Advances in chemotherapy and biotherapy of endocrine tumors
Öberg, K. (1998) · Current Opinion in Oncology · doi:10.1097/00001622-199801000-00010 · Cited by 59
Neurotensin enhances IL-1 production by activated alveolar macrophages.
Lemaire, I. B. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.9.2983 · Cited by 59
Frühwald, M. C., O'Dorisio, M. S., Pietsch, T., & Reubi, J. C. (1999) · Pediatric Research · doi:10.1203/00006450-199905010-00016 · Cited by 59
Self-citationHofland, L. J., van Koetsveld, P. M., Wouters, N. M. H., Waaijers, M., Reubi, J. C., & Lamberts, S. W. J. (1992) · Endocrinology · doi:10.1210/endo.131.2.1322274 · Cited by 58
Self-citationStroh, T., Jackson, A. C., Sarret, P., Farra, C. D., Vincent, J., Kreienkamp, H., Mazella, J., & Beaudet, A. (2000) · Endocrinology · doi:10.1210/endo.141.1.7259 · Cited by 58
Mantyh, C. R., Pappas, T. N., & Vigna, S. R. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90226-7 · Cited by 57
Ferris, H. A., Carroll, R. E., Lorimer, D. L., & Benya, R. V. (1997) · Peptides · doi:10.1016/s0196-9781(97)00127-7 · Cited by 56
Visualization of the thymus by substance P receptor scintigraphy in man
van Hagen, P. M., Breeman, W. A. P., Reubi, J. C., Postema, P. T., van den Anker-Lugtenburg, P. J., Kwekkeboom, D. J., Laissue, J. A., Waser, B., Lamberts, S. W. J., Visser, T. J., et al. (1996) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/bf01254476 · Cited by 56
Self-citationRelevant genomics of neurotensin receptor in cancer.
Elek, J., Pinzon, W., Park, K. H., & Narayanan, R. (2000) · PubMed · Cited by 56
Hessenius, C., Bäder, M., MEINHOLD, H., Böhmig, M., Faiss, S., Reubi, J., & Wiedenmann, B. J. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590000325 · Cited by 53
Self-citationVIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells
Moody, T. W., Leyton, J., Chan, D. C. F., Brenneman, D. C., Fridkin, M., Gelber, E., Levy, A., & Gozes, I. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1017994722130 · Cited by 52
Gastrin Releasing Peptide-Preferring Bombesin Receptors Mediate Growth of Human Renal Cell Carcinoma
Pansky, A., de Weerth, A., Fasler‐Kan, E., Boulay, J., Schulz, M., Ketterer, S., SELCK, C., Beglinger, C., von Schrenck, T., & Hildebrand, P. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1181409 · Cited by 52
Expression of Somatostatin Receptor Subtype 1–5 Genes in Human Pancreatic Cancer
Fisher, W. E., Doran, T., Muscarella, P., Boros, L. G., Ellison, E. C., & Schirmer, W. J. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.4.322 · Cited by 51
Kiaris, H., Schally, A. V., Nagy, A., Szepesházi, K., Hébert, F., & Halmos, G. B. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00437-8 · Cited by 50
Session 5: Trophic Effects of Gastrin
Håkanson, R., & Sundler, F. (1991) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529109093190 · Cited by 43
Sestini, R., Orlando, C., Peri, A., Tricarico, C., Pazzagli, M., Serio, M., Pagani, A., Bussolati, G., Granchi, S., & Maggi, M. (1996) · PubMed · Cited by 43
Frendo, J., Pichaud, F., Delage-Mourroux, R., Bouizar, Z., Segond, N., Moukhtar, M. S., & Jullienne, A. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)80503-2 · Cited by 42
Analysis of somatostatin receptor subtype mRNA expression in human breast cancer
Evans, A., Crook, T., Laws, S., Gough, A. C., Royle, G. T., & Primrose, J. M. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.143 · Cited by 39
Neuropeptide Modulation of the Immune Response in Gut Associated Lymphoid Tissue
O'Dorisio, M. S. (1988) · International Journal of Neuroscience · doi:10.3109/00207458809000497 · Cited by 38
Inhibition of human neuroblastoma growth by a specific VIP antagonist
Lilling, G., Wollman, Y., Goldstein, M. N., Rubinraut, S., Fridkin, M., Brenneman, D. E., & Gozes, I. (1994) · Journal of Molecular Neuroscience · doi:10.1007/bf02736724 · Cited by 38
Straub, B., Müller, M., Krause, H., Schrader, M., Goessl, C. D., Heicappell, R., & Miller, K. (2001) · PubMed · Cited by 37
Intraoperative tumour detection using 111 In-DTPA- D -Phe 1 -octreotide and a scintillation detector
Benjegård, S. A., Forssell-Aronsson, E. B., Wängberg, B., Skånberg, J., Nilsson, O., & Ahlman, H. (2001) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590100600 · Cited by 35
Potent Somatostatin Undecapeptide Agonists Selective for Somatostatin Receptor 1 (sst1)
Rivier, J., Hoeger, C. A., Érchegyi, J., Gulyás, J., DeBoard, R., Craig, A. G., Koerber, S. C., Wenger, S., Waser, B., Schaer, J., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010037+ · Cited by 35
Self-citationCharacterization of functional neurotensin receptors on human lymphocytes.
Evers, B. M., Bold, R. J., Ehrenfried, J. A., et al. (1994) · PubMed · Cited by 35
Schindler, M., Holloway, S., Humphrey, P. P. A., Waldvogel, H. J., Faull, R. L. M., Berger, W., & Emson, P. C. (1998) · Neuroreport · doi:10.1097/00001756-199802160-00027 · Cited by 33
Alberini, J., Meunier, B., Denzler, B., Devillers, A., Tas, P., Dazord, L., Simple, T. L., Laissue, J. A., de Jong, R., Cloirec, J. L., et al. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006447325077 · Cited by 32
Self-citationWong, W., & Minchin, R. F. (1996) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(96)00074-x · Cited by 30
VPAC1Receptors and Lung Cancer
Moody, T. W., Walters, J. L., Casibang, M., Zia, F. Z., & Gozes, Y. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06947.x · Cited by 29
Functional role of somatostatin receptors in neuroendocrine and immune cells.
Hofland, L. J., van Hagen, P. M., & Lamberts, S. W. J. (1999) · PubMed · Cited by 29
Carroll, R. E., Carroll, R., & Benya, R. V. (1999) · Peptides · doi:10.1016/s0196-9781(98)00164-8 · Cited by 28
sst5 somatostatin receptor mRNA induction by mitogenic activation of human T-lymphocytes
Ghamrawy, C. E., Rabourdin‐Combe, C., & Krantic, S. M. (1999) · Peptides · doi:10.1016/s0196-9781(99)00036-4 · Cited by 27
Duet, M., Ajzenberg, C., Benelhadj, S., et al. (1999) · PubMed · Cited by 24
Schwärzler, A., Kreienkamp, H., & Richter, D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.13.9557 · Cited by 23
Gastrin, growth, and colon neoplasia
Dockray, G. J. (2000) · Gut · doi:10.1136/gut.47.6.747 · Cited by 22
Somatostatin Receptor Manipulation
Visser-Wisselaar, H. A., Hofland, L. J., van Uffelen, C. J. C., van Koetsveld, P. M., & Lamberts, S. W. J. (2009) · Digestion · doi:10.1159/000201383 · Cited by 20
Blower, P. J., Puncher, M. R. B., Kettle, A. G., George, S. E., Dorsch, S., Leak, A. M., Naylor, L. H., & O'Doherty, M. J. (1998) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050200 · Cited by 20
Pilichowska, M. E., Kimura, N., Schindler, M., Suzuki, A., Yoshida, R., & Nagura, H. (2000) · Endocrine Pathology · doi:10.1385/ep:11:1:57 · Cited by 17
Bussolati, G., Chinol, M., Chini, B., Nacca, A., Cassoni, P., & Paganelli, G. (2001) · PubMed · Cited by 13
Camby, I., Salmon, I. J., Oiry, C., et al. (1996) · Neuropeptides · doi:10.1016/s0143-4179(96)90006-2 · Cited by 10
DOTA‐NOC, A high affinity ligand of the somatostatin receptor subtypes 2, 3 and 5 for radiotherapy
Schmitt, J. S., Wild, D., Ginj, M., Reubi, J. C., Waser, B., de Jong, M., Bernard, B. F., Krenning, E. P., & Mäcke, H. R. (2001) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.25804401246 · Cited by 10
Self-citationHannon, J. P., Langenegger, D., Waser, B., Hoyer, D., & Reubi, J. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01223-7 · Cited by 3
Self-citationLipton (1995) · Pure Amsterdam UMC · doi:10.1002/1097-0142(19950415)75:8 · Cited by 1
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy
Pham, T. C., Nguyen, V.-N., Choi, Y., Lee, S., & Yoon, J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00381 · Cited by 1,813
Gabriel, M., Decristoforo, C., Kendler, D., Dobrozemsky, G., Heute, D., Uprimny, C., Kovacs, P., Von Guggenberg, E., Bale, R., & Virgolini, I. J. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.035667 · Cited by 1,010
Wadas, T. J., Wong, E. H., Weisman, G. R., & Anderson, C. J. (2010) · Chemical Reviews · doi:10.1021/cr900325h · Cited by 924
Imhof, A., Brunner, P., Marincek, N., Briel, M., Schindler, C., Rasch, H., Mäcke, H. R., Rochlitz, C., Müller-Brand, J., & Walter, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7873 · Cited by 641
Metadata
- Authors
- Reubi, J. C.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2003-08-01
- Volume
- 24
- Issue
- 4
- Pages
- 389-427
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2045681528
- Cited by
- 1,131
- References
- 249
- FWCI
- 29.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.